Summary of the technology
The device incorporates an active drug delivery PEP valve device that provides active, accumulative dosing of large volume of aerosolized drug or air. This technology enables the distribution of the substance to the lower respiratory system. also incorporated is a Venturi-based insufflation-exhalation system that simulates cough by predefined parameters activated independently or by stimuli from the patient
Project ID : 40-2018-4614
Description of the technology
Medical Devices, Drug Delivery, Respiratory System
Current development stage
Proof-of- Concept and a demonstration designed.
A prototype suitable for mass production may be produced within 12 months.
Spinal cord injuries (SCI) impair the ability to breathe deeply and cough forcefully. As a result, SCI patients cannot clearthemucusproduced in the airway system, which can lead to morbidity and mortality associated with respiratory infections and decreased quality of life.
Current solutions vary and include one of the possible techniques:
- The utilization of professional physiotherapists who perform physical maneuvers that assists patients to cough.
- Various expensive hospital coughers that are immobile and not adjusted for home usage and require the expertise and assistance of medical personnel.
- Various mechanical inflation-exhalation devices that are fitted for home use, but currently can only be used with others' assistance.
We deliver an efficient, convenient, cost-effective and accessible way to produce cough among SCI patient that can be operated solely by the patient.
The device incorporates an active drug delivery PEP valve device that provides active, accumulative dosing of large volume of aerosolized drug or air. This technology enables the distribution of the substance to the lower respiratory system.
In addition, we incorporate a venturi-based insufflation-exhalation system that simulates cough by predefined parameters activated independently or by stimuli from the patient.
Unlike standard nebulizers and inhalers, our device actively delivers air or drug using large volume of pressurized air directly to the target site. As a result, it does not rely on distribution, the user’s breath or diffusion. Therefore, thr distribution either could go all the way to the alveoli itself, or directly to obstructed or blocked region.
SCI patients suffer from 38,000 complications per year due to impaired coughing. The average cost per patient reaches up to $66K.
SVP BUSINESS DEVELOPMENT
HUJI, School of Computer Science and Engineering
About Yissum - Research Development Company of the Hebrew University
Technology Transfer Office from IsraelYissum - Research Development Company of the Hebrew University
Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. Founded in 1964 to protect and commercialize the Hebrew University’s intellectual property. Ranked among the top technology transfer companies, Yissum has registered over 8,900 patents covering 2,500 inventions; has licensed out 800 technologies and has spun-off 90 companies. Products that are based on Hebrew University technologies and were commercialized by Yissum generate today over $2 Billion in annual sales.